• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

A Timeline of US Biosimilar Adalimumab Launch Dates

Article

AbbVie has struck agreements with multiple developers over biosimilar adalimumab, forestalling US market entry until 2023. Here's when each product could potentially reach US patients.

AbbVie has struck agreements with multiple developers over biosimilar adalimumab, forestalling US market entry until 2023. Here's when each product could reach US patients.

Recent Videos
global biosimilars week join the movement
Sophia Humphreys, PharmD
Lakesha Farmer from Cencora
Prerakkumar Parikh, PharmD
Chelsee Jensen, PharmD, BCPS
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Julie Reed
Julie Reed, executive director of the Biosimilars Forum
Fran Gregory, PharmD, vice president of emerging therapies, Cardinal Health
Related Content
© 2024 MJH Life Sciences

All rights reserved.